AL-'AQAR HEALTHCARE REIT |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.29 MYR | -0.77% |
|
-0.77% | +4.03% |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
Strengths
- The group's activity appears highly profitable thanks to its outperforming net margins.
- The company is one of the best yield companies with high dividend expectations.
- Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
Weaknesses
- As estimated by analysts, this group is among those businesses with the lowest growth prospects.
- The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Sector: Specialized REITs
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +4.03% | 229M | - | ||
| +8.94% | 700M | C+ | ||
| -5.74% | 612M | - | - | |
| -9.55% | 602M | - | - | |
| -5.26% | 432M | - | - | |
| +0.41% | 428M | - | - | |
| -12.30% | 354M | - | - | |
| -10.61% | 297M | - | - | |
| +1.62% | 236M | - | - | |
| -16.12% | 199M | - | - |
Investor Rating
Trading Rating
-
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
-
Profitability
Finances
-
Valuation
P/E ratio
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
-
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
- Stock Market
- Equities
- ALAQAR Stock
- Ratings Al-'Aqar Healthcare REIT
